Alprazolam Safety in G6PD Deficiency
Alprazolam can be used safely in patients with G6PD deficiency without dose adjustment, as benzodiazepines have not been shown to cause hemolytic crises in this population.
Evidence Supporting Safe Use
Benzodiazepines, including alprazolam, are not listed among the seven medications definitively contraindicated in G6PD deficiency (dapsone, methylene blue, nitrofurantoin, phenazopyridine, primaquine, rasburicase, and tolonium chloride). 1, 2
A comprehensive perioperative review specifically identified benzodiazepines as safe medications that have not been shown to cause hemolytic crises in G6PD-deficient patients. 3
The most rigorous evidence-based review of medications in G6PD deficiency found no evidence contraindicating the use of benzodiazepines in normal therapeutic doses. 2
Clinical Rationale
The mechanism of drug-induced hemolysis in G6PD deficiency involves oxidative stress overwhelming the reduced antioxidant capacity of red blood cells. 4
Benzodiazepines do not possess oxidant properties that would trigger hemolysis in G6PD-deficient red blood cells, unlike the seven definitively contraindicated medications that are potent oxidants. 1, 3
Practical Management
No special monitoring, dose adjustment, or precautions are required when prescribing alprazolam to G6PD-deficient patients. 2, 3
Standard anxiolytic dosing can be used without concern for hemolytic complications. 3
Common Pitfall to Avoid
Do not confuse alprazolam with the truly contraindicated medications. Many compounds have been wrongly cited as causing hemolysis because they were administered during infection-related hemolytic episodes, leading to inappropriate medication restrictions. 2
The confusion surrounding medication safety in G6PD deficiency has caused unnecessary distress to patients who receive conflicting advice; alprazolam should not be among the restricted medications. 2